HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jong Ho Park Hae Won Lee Young Mog Shim Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, J. H. Articles by Shim, Y. M. Search for Related Content PubMed PubMed Citation Articles by Park, J. H. Articles by Shim, Y. M. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2005;27:1086-1091
© 2005 Elsevier Science NL

Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer

^a Department of Thoracic Surgery, Korea Cancer Center Hospital, Nowon-Ku Gongneung-Dong 215–4, Seoul 139–706, South Korea
^b Department of Internal Medicine, Korea Cancer Center Hospital, Nowon-Ku Gongneung-Dong 215–4, Seoul 139–706, South Korea

Received 3 September 2004; received in revised form 18 January 2005; accepted 20 January 2005.

^* Corresponding author. Tel.: 822-970-1240; fax: 822-970-2401. (E-mail: jhpark{at}kcch.re.kr).

Objective: Surgery constitutes the mainstay of treatment in stage I non-small cell lung cancer (NSCLC). However, a significant fraction of patients after surgical resection die mainly due to systemic relapse. Nonetheless, the best adjuvant treatment to improve survival and decrease relapse rate remains as an ever controversial issue. Therefore, we conducted a randomized trial to determine whether postoperative adjuvant chemotherapy is beneficial in prolonging survival and decreasing recurrence in patients with completely resected stage I NSCLC. Methods: It was designed as a randomized, prospective two-armed study with surgery only (control group, 59 patients) versus surgery plus adjuvant MVP (mitomycin C, vinblastin and cisplatin) chemotherapy (study group, 59 patients). Results: Data for all the patients were complete. Twenty-four patients in the control group and nine patients in the study group experienced tumor recurrence during the follow-up. Neither histological type nor surgical extent correlated with recurrence. However, the addition of adjuvant MVP chemotherapy could decrease the rate of recurrence and the incidence of cancer-related death after surgery in the patients of stage I NSCLC (P<0.05). We followed up at least 5 years, and the duration of mean follow-up was 7.3 years. The rates of the loco-regional and distant metastases were 3.4 and 40.7% in the control group, and 3.4 and 11.9% in the study group, respectively. The 5- and 10-year survival rates were 74.6 and 56.3% in the control group, and 81.4 and 65.0% in the study group, respectively (P=0.19, log-rank test). The 5- and 10-year disease-free survival rates were 64.8 and 54.8% in the control group, and 88.8 and 76.8% in the study group, respectively (P=0.002, log-rank test). Conclusions: Our results suggest that the addition of adjuvant MVP chemotherapy may reduce the incidence of distant metastasis and prolong the disease-free survival of the patients with stage I NSCLC after surgery.

Key Words: Stage I • Non-small cell lung cancer • Adjuvant therapy • MVP chemotherapy

This article has been cited by other articles:

				K. M.W. Pisters, W. K. Evans, C. G. Azzoli, M. G. Kris, C. A. Smith, C. E. Desch, M. R. Somerfield, M. C. Brouwers, G. Darling, P. M. Ellis, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline J. Clin. Oncol., December 1, 2007; 25(34): 5506 - 5518. [Abstract] [Full Text] [PDF]